Loading
A phase 1/2 trial of Pembrolizumab in endometrial cancer, head and neck squamous cell carcinoma, melanoma and non-small-cell lung cancer, run by GV20 Therapeutics, now recruiting.
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT05669430 by GV20 Therapeutics, with 365 participants planned, started 2023-03-23 and due to reach its primary completion in 2026-12-15. Interventions recorded: GV20-0251 and GV20-0251 and Pembrolizumab [KEYTRUDA®].
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GV20 Therapeutics, Endometrial cancer, Head and neck squamous cell carcinoma, Melanoma and the tag pipeline.
Shares Merck & Co. (MSD), Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Endometrial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/